|
"BCR/ABL-PI-3k-ROS pathway induce genomic instability ...."
|
5R01CA134458-02
|
$307,951
|
$307,951
|
SKORSKI, TOMASZ
|
TEMPLE UNIVERSITY
|
|
???Novel melampomagnolide B-based prodrugs for the treatment of leukemia???
|
1R01CA158275-01A1
|
$326,488
|
$326,488
|
Crooks, Peter
|
UNIVERSITY OF KENTUCKY
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120-02060
|
$213,606
|
$85,442
|
Rothman, Nat
|
DCEG (NCI)
|
|
A CROSS-SECTIONAL STUDY OF OCCUPATIONAL EXPOSURE TO TRICHLOROETHYLENE, CHROMOSOMA
|
ZIA CP010121-10363
|
$17,250
|
$17,250
|
Lan, Qing
|
DCEG (NCI)
|
|
A Novel Modulator of Notch in Acute Lymphoblastic Leukemia
|
1R21CA161436-01
|
$207,634
|
$207,634
|
Liang, Chengyu
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
A Novel Screen for Compounds that Outflank BCR-ABL Drug-Resistance
|
5R01CA136699-03
|
$305,910
|
$305,910
|
COLICELLI, JOHN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
A Novel sequencing-based approach to discovering rare genetic factors for ALL.
|
5K08CA140720-02
|
$149,387
|
$149,387
|
Druley, Todd
|
WASHINGTON UNIVERSITY
|
|
A Novel Strategy for Defining and Targeting Cancer Addiction to Anti-Apoptotic BC
|
5R01CA129974-05
|
$315,153
|
$315,153
|
LETAI, ANTHONY
|
DANA-FARBER CANCER INSTITUTE
|
|
A Phase I/II Trial of Eltrombopag in Elderly Acute Myeloid Leukemia Patients
|
5R21CA153018-02
|
$322,040
|
$322,040
|
Carroll, Martin
|
UNIVERSITY OF PENNSYLVANIA
|
|
A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refracto
|
1R21CA159265-01
|
$272,667
|
$272,667
|
LORIAUX, MARC
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
|
A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL
|
1R21CA161688-01
|
$360,330
|
$360,330
|
Burke, Michael
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$370,199
|
$37,019
|
Tosato, Giovanna
|
CCR (NCI)
|
|
A Role for PML in Genome Stability and DNA Damage Response
|
5R01CA055577-18
|
$256,139
|
$204,911
|
CHANG, KUN-SANG
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$1,178,242
|
$58,912
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Aberrant activation of HGF/MET signaling as a therapeutic target in AML
|
1K08CA160660-01
|
$156,330
|
$156,330
|
Kentsis, Alex
|
DANA-FARBER CANCER INSTITUTE
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-35
|
$7,696,742
|
$538,772
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-35S1
|
$50,000
|
$3,500
|
LERMAN, CARYN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Academic Training in Medical Oncology
|
3T32CA009297-28S1
|
$66,919
|
$6,692
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Academic Training in Medical Oncology
|
5T32CA009297-28
|
$316,308
|
$31,631
|
RIBAS, ANTONI
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$328,740
|
$164,369
|
Aplan, Peter
|
CCR (NCI)
|
|
Adoptive immunotherapy after umbilical cord blood transplant
|
5R01CA124782-05
|
$283,822
|
$283,822
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adoptive Immunotherapy of Cancer with IL-12 Secreting Tumor-Targeted T cells
|
5R01CA138738-03
|
$381,617
|
$381,617
|
Brentjens, Renier
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Adoptive T-Cell Therapy for Acute Leukemia
|
5R21CA132277-02
|
$310,970
|
$310,970
|
BALL, EDWARD
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Adult Leukemia Research Center
|
5P01CA018029-36
|
$5,431,018
|
$5,431,018
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Agricultural Health Study - Biomarkers of Exposures and Effects in Agriculture
|
ZIA CP010119-10527
|
$347,286
|
$173,642
|
Alavanja, Michael
|
DCEG (NCI)
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
5R01CA139032-03
|
$322,040
|
$322,040
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
ALL therapy and developing brains: MRI measures, genetic factors and cognition
|
2R01CA090246-06A2
|
$380,224
|
$380,224
|
REDDICK, WILBURN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi
|
1K23CA154532-01
|
$169,590
|
$169,590
|
Bleakley, Marie
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$58,058
|
$38,899
|
Kochenderfer, James
|
CCR (NCI)
|
|
Alloreactive Regulatory T cells control GVHD and maintain GVL effect
|
2R01CA118116-04A1
|
$291,425
|
$291,425
|
YU, XUE-ZHONG
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Altered Glycolytic Pathway in in vitro Models of leukemia developed in hypoxia
|
1R15CA159308-01
|
$444,394
|
$444,394
|
Kang, Min
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Analysis of higher order chromatin structures in normal and cancer epigenomes
|
5R01CA140485-02
|
$333,111
|
$333,111
|
Kim, Tae Hoon
|
YALE UNIVERSITY
|
|
Analysis of the leukemic stem cell niche in chronic myeloid leukemia
|
5K08CA138916-02
|
$160,016
|
$160,016
|
Krause, Daniela
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,179,485
|
$58,974
|
Oberholtzer, J.
|
CCR (NCI)
|
|
Animal models to study the role of INK4b loss in human acute myeloid leukemia
|
ZIA BC 011027
|
$721,379
|
$721,378
|
Wolff, Linda
|
CCR (NCI)
|
|
Antibody Engineering for Therapy and Diagnosis of Hematologic Malignancies
|
ZIA BC 010647
|
$388,021
|
$194,010
|
Rader, Christoph
|
CCR (NCI)
|
|
Antibody V Gene Expression B Cell Lymphocytic Leukemia
|
5R37CA049870-24
|
$322,228
|
$322,228
|
KIPPS, THOMAS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Antileukemic effort of NK cells in HCT for pediatric AML
|
5R01CA120583-05
|
$347,302
|
$347,302
|
LEUNG, WING
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Antitumor-Antibiotics from Marine Microorganisms
|
5R37CA044848-25
|
$373,010
|
$149,204
|
FENICAL, WILLIAM
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Apoptosis Induced by Glucocorticoids and MEK1/2 Inhibitors in Leukemia
|
4R01CA134473-03
|
$237,412
|
$237,412
|
HARADA, HISASHI
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
Application of 454 Sequencing to Cancer Epigenomics
|
5R33CA134304-03
|
$305,392
|
$305,392
|
SHI, HUIDONG
|
GEORGIA HEALTH SCIENCES UNIV RES INSTIT
|
|
Aptamer Based Technology for Molecular Analysis of Leukemia
|
5R01CA129311-04
|
$294,868
|
$294,868
|
Li, Ying
|
UNIVERSITY OF FLORIDA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S1
|
$139,575
|
$2,792
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
3P30CA023074-33S2
|
$75,000
|
$1,500
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arizona Cancer Center-Cancer Center Support Grant
|
5P30CA023074-33
|
$3,953,813
|
$79,076
|
Alberts, David
|
UNIVERSITY OF ARIZONA
|
|
Arsenic Trioxide and Acute Myeloid Leukemia
|
5R01CA093533-08
|
$247,445
|
$247,445
|
JING, YONGKUI
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Assays for Screening Histone Modifications in Cancer
|
5R01CA107106-06
|
$226,740
|
$226,740
|
FREITAS, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
ATBC Study
|
ZIA CP010195-03031
|
$828,679
|
$24,860
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Augmenting Antitumor Immunity after Allografting
|
5R01CA122779-04
|
$281,662
|
$281,662
|
LUZNIK, LEO
|
JOHNS HOPKINS UNIVERSITY
|
|
Autologous T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011413
|
$116,117
|
$58,058
|
Kochenderfer, James
|
CCR (NCI)
|
Total relevant funding to Leukemia for this search: $227,025,963
|